OREANDA-NEWS The Russian Direct Investment Fund (RDIF) has signed an agreement with SAFFARM, a subsidiary of the Indian pharmaceutical company Safecon Lifesciences, and the Biopharmaceutical Center (owned by the Indian Anicare Bio Science) to invest in the production of medicines and pharmaceutical ingredients. This is stated in the press service of the foundation.

SAFFARM plans to build a pharmaceutical complex and a factory of active pharmaceutical ingredients in the Murmansk Region for the production of general, hormonal and oncological drugs, the fund added.

RDIF investments in the project are aimed at import substitution of a number of medicines, while some of them have not been produced in Russia before. The estimated capacity of the pharmaceutical complex will be 1.3 billion units of medicines and 1.8 thousand tons of active pharmaceutical ingredients per year with the possibility of expanding production volumes in the future. The launch of the enterprise is expected in 2027.

"The launch of enterprises in the Murmansk region will make it possible to produce new pharmaceutical products that were not previously produced in Russia, which will expand the list of available drugs and reduce dependence on foreign supplies. Thus, the investment project makes an important contribution to ensuring the drug sovereignty of Russia," said Kirill Dmitriev, Director General of the RDIF.